Addgene

Recent papers from Addgene

1. Evaluation of Antisense Oligonucleotide-Associated Neuronal Lysosomal ChangesNucleic Acid Therapeutics · 2026
2. Recovering signatures of archaic hominin introgression using ancestral recombination graphsScience · 2026
3. The Diversifying Distribution Trends of Maturing CRISPR Technologies by AddgeneThe CRISPR Journal · 2026
4. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphomaBlood Advances · 2026
5. Recommendation Statement for the Validation, Implementation, and Clinical Application of Artificial Intelligence Within a Clinical Laboratory from the Digital Pathology AssociationAI in Precision Oncology · 2026
6. Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical ImplicationsClinical Cancer Research · 2026
7. IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC).Journal of Clinical Oncology · 2026
8. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC).Journal of Clinical Oncology · 2026
9. Examining the tumor microbiology and microenvironment of patients with triple-negative inflammatory breast cancer receiving KEYNOTE-522.Journal of Clinical Oncology · 2026
10. A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune ArchitectureCancer Discovery · 2026
11. Evaluation of steroid toxicity using the Glucocorticoid Toxicity Index-Metabolic Domains instrument in adults with myasthenia gravis: a real-world study in the USAJournal of Comparative Effectiveness Research · 2026
12. Immunotherapy Response and Survival Outcome by Immunophenotypic Signature in Non–Small Cell Lung CancerJCO Precision Oncology · 2026
13. Abstract CT277: IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC)Cancer Research · 2026
14. Analysis of Clinical Benefit Using DNG64- CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing CancersAnticancer Research · 2026
15. Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsCancer Discovery · 2026
16. Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient‐Centric Treatment GoalEuropean Journal of Neurology · 2026
17. Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R)Quality of Life Research · 2026
18. The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia GravisSHILAP Revista de lepidopterología · 2026
19. Recovering signatures of archaic introgression using ancestral recombination graphs2026
20. A Cross-Species Enhancer-AAV Toolkit for Cell Type-Specific Targeting Across the Basal Ganglia2026